The the DT
SQ sq NN
tree tree NN
sublingual sublingual JJ
immunotherapy immunotherapy NN
-LRB- -lrb- -LRB-
SLIT slit NN
-RRB- -rrb- -RRB-
- - :
tablet tablet NN
containing contain VBG
allergen allergen NN
extracts extract NNS
with with IN
the the DT
major major JJ
allergen allergen NN
Bet bet NN
v v LS
1 1 CD
from from IN
birch birch JJ
pollen pollen NN
is be VBZ
currently currently RB
being be VBG
developed develop VBN
for for IN
the the DT
treatment treatment NN
of of IN
tree tree NN
pollen-induced pollen-induced JJ
allergic allergic JJ
rhinitis/conjunctivitis rhinitis/conjunctivitis NN
with with IN
or or CC
without without IN
asthma asthma NN
The the DT
aim aim NN
of of IN
this this DT
Phase phase NN
II ii CD
trial trial NN
was be VBD
to to TO
investigate investigate VB
the the DT
dose-related dose-related JJ
efficacy efficacy NN
and and CC
safety safety NN
of of IN
the the DT
SQ sq NN
tree tree NN
SLIT-tablet slit-tablet NN
This this DT
study study NN
was be VBD
a a DT
randomized randomize VBN
parallel-group parallel-group NN
double-blind double-blind JJ
placebo-controlled placebo-controlled JJ
multi-national multi-national JJ
trial trial NN
conducted conduct VBN
in in IN
Europe Europe NNP
A a DT
total total NN
of of IN
637 637 CD
participants participant NNS
were be VBD
randomized randomize VBN
equally equally RB
to to TO
receive receive VB
placebo placebo NN
or or CC
treatment treatment NN
with with IN
the the DT
SQ sq NN
tree tree NN
SLIT-tablet slit-tablet NN
in in IN
doses dose NNS
of of IN
0.5 0.5 CD
1 1 CD
2 2 CD
4 4 CD
7 7 CD
or or CC
12 12 CD
development development NN
units unit NNS
-LRB- -lrb- -LRB-
DU DU NNP
-RRB- -rrb- -RRB-
Treatment treatment NN
was be VBD
initiated initiate VBN
~ ~ RB
16 16 CD
weeks week NNS
before before IN
onset onset NN
of of IN
the the DT
2013 2013 CD
birch birch NN
pollen pollen NN
season season NN
-LRB- -lrb- -LRB-
BPS bps NN
-RRB- -rrb- -RRB-
and and CC
was be VBD
continued continue VBN
throughout throughout IN
the the DT
BPS bps NN
with with IN
a a DT
total total JJ
duration duration NN
of of IN
at at IN
least least JJS
6 6 CD
months month NNS
During during IN
the the DT
BPS BPS NNP
and and CC
tree tree NN
pollen pollen NN
season season NN
-LRB- -lrb- -LRB-
TPS tps NN
-RRB- -rrb- -RRB-
subjects subject NNS
assessed assess VBN
rhinoconjunctivitis rhinoconjunctivitis NN
symptoms symptom NNS
and and CC
medication medication NN
use use NN
on on IN
a a DT
daily daily JJ
basis basis NN
in in IN
an a DT
electronic electronic JJ
diary diary NN
weekly weekly JJ
assessments assessment NNS
of of IN
rhinoconjunctivitis rhinoconjunctivitis NN
quality quality NN
of of IN
life life NN
were be VBD
also also RB
made.Analysis made.analysis NN
of of IN
the the DT
average average JJ
daily daily JJ
symptom symptom NN
score score NN
during during IN
the the DT
BPS BPS NNP
and and CC
the the DT
TPS tps NN
showed show VBD
that that IN
the the DT
difference difference NN
between between IN
active active JJ
treatment treatment NN
and and CC
placebo placebo NN
was be VBD
statistically statistically RB
significant significant JJ
for for IN
the the DT
7 7 CD
DU DU NNP
group group NN
-LRB- -lrb- -LRB-
BPS bps NN
P p NN
0.02 0.02 CD
TPS tps NN
P p NN
0.03 0.03 CD
-RRB- -rrb- -RRB-
with with IN
no no DT
clear clear JJ
dose-response dose-response JJ
relationship relationship NN
All all DT
doses dose NNS
of of IN
the the DT
SQ sq NN
tree tree NN
SLIT-tablet slit-tablet NN
induced induce VBD
changes change NNS
from from IN
baseline baseline NN
in in IN
birch-specific birch-specific JJ
IgE ige NN
and and CC
IgG4 igg4 NN
that that WDT
were be VBD
statistically statistically RB
significant significant JJ
compared compare VBN
with with IN
placebo placebo NN
at at IN
all all DT
time time NN
points point NNS
assessed assess VBN
-LRB- -lrb- -LRB-
P p NN
< < JJR
0.0001 0.0001 CD
-RRB- -rrb- -RRB-
with with IN
a a DT
clear clear JJ
dose-response dose-response JJ
relationship relationship NN
for for IN
birch birch NN
specific specific JJ
IgG4 igg4 NN
In in IN
general general JJ
the the DT
SQ sq NN
tree tree NN
SLIT-tablet slit-tablet NN
was be VBD
well well RB
tolerated tolerate VBN
with with IN
the the DT
majority majority NN
of of IN
treatment-related treatment-related JJ
adverse adverse JJ
events event NNS
-LRB- -lrb- -LRB-
≥ ≥ CD
95 95 CD
-RRB- -rrb- -RRB-
being be VBG
mild mild JJ
or or CC
moderate moderate JJ
in in IN
severity severity NN
The the DT
most most RBS
frequently frequently RB
reported report VBN
treatment-related treatment-related JJ
adverse adverse JJ
events event NNS
were be VBD
generally generally RB
related relate VBN
to to TO
the the DT
sublingual sublingual JJ
administration administration NN
of of IN
the the DT
tablet tablet NN
-LRB- -lrb- -LRB-
ie ie FW
they they PRP
occurred occur VBD
in in IN
the the DT
oral oral JJ
cavity cavity NN
-RRB- -rrb- -RRB-
The the DT
results result NNS
from from IN
this this DT
trial trial NN
suggest suggest VBP
that that IN
the the DT
SQ sq NN
tree tree NN
SLIT-tablet slit-tablet NN
in in IN
doses dose NNS
up up RB
to to TO
12 12 CD
DU DU NNP
has have VBZ
a a DT
tolerability tolerability NN
profile profile NN
suitable suitable JJ
for for IN
at-home at-home JJ
administration administration NN
The the DT
immunomodulatory immunomodulatory JJ
changes change NNS
indicate indicate VBP
a a DT
dose-response dose-response JJ
relationship relationship NN
but but CC
clinical clinical JJ
efficacy efficacy NN
parameters parameter NNS
were be VBD
inconclusive inconclusive JJ
probably probably RB
due due JJ
to to TO
low low JJ
pollen pollen NN
counts count NNS
emphasizing emphasize VBG
the the DT
importance importance NN
of of IN
pollen pollen NN
exposure exposure NN
for for IN
the the DT
outcome outcome NN
of of IN
a a DT
pollen pollen NN
allergy allergy NN
immunotherapy immunotherapy NN
trial trial NN
EudraCT EudraCT NNP
no no DT
2012-000031-59 2012-000031-59 CD
